{
  "url": "https://openlegislation.uk/misuse-of-drugs-regulations-2001/schedule-5/paragraph-10",
  "json_url": "https://openlegislation.uk/misuse-of-drugs-regulations-2001/schedule-5/paragraph-10.json",
  "legislation": "uksi/2001/3998",
  "legislation_title": "The Misuse of Drugs Regulations 2001",
  "legislation_url": "https://openlegislation.uk/misuse-of-drugs-regulations-2001",
  "path": "schedule/5/paragraph/10",
  "kind": "paragraph",
  "number": "10",
  "heading": null,
  "text": "A liquid formulation—\n(a) containing cannabidiol obtained by extraction and purification from cannabis;\n(b) where the concentration of—\n(i) delta-9-tetrahydrocannabinol is not more than 0.1 milligram per millilitre; and\n(ii) cannabidiol is 95-105 milligrams per millilitre;\n(c) which is presented in a bottle, as an oral solution for oral administration; and\n(d) which was approved for marketing by the European Commission on 19th September 2019.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Sch. 5 para. 10 inserted (24.6.2020) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2020 (S.I. 2020/559), regs. 1(1), 2(4)"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2001/3998/schedule/5/paragraph/10",
    "retrieved_at": "2026-10-29T07:18:47.393467+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}